EUGIA PHARMA SPECLTS
GenericsEUGIA PHARMA SPECLTS is a generic drug manufacturer focused on Oncology, Infectious Disease, Immunology.
EUGIA PHARMA SPECLTS's Key Drugs
EUGIA PHARMA SPECLTS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
EUGIA PHARMA SPECLTS's Recent FDA Approvals
New NDA/BLA approvals for EUGIA PHARMA SPECLTS over the last two years — novel drugs only, excluding generics and label supplements.
EUGIA PHARMA SPECLTS's Therapeutic Areas
EUGIA PHARMA SPECLTS's approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Infectious Disease, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
EUGIA PHARMA SPECLTS's Top Competitors
EUGIA PHARMA SPECLTS's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Johnson & Johnson, and PF PRISM CV. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
EUGIA PHARMA SPECLTS Pipeline Snapshot
Active clinical trials for EUGIA PHARMA SPECLTS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2002-11-27
- Latest
- 2026-06-10
- Applications
- 26